A Multiple Ascending Dose Study of ACN00177 in Subjects With CBS Deficiency

Status:
Recruiting

Trial end date:
2022-03-01

Target enrollment:

Participant gender:

The purpose of this study is to evaluate the safety and tolerability of ACN00177 in up to 25 subjects with homocystinuria due to CBS deficiency.

Phase 1/Phase 2

Aeglea Biotherapeutics